Immunome (IMNM) Equity Ratio (2023 - 2025)
Immunome (IMNM) has disclosed Equity Ratio for 3 consecutive years, with 0.93 as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Equity Ratio rose 23.13% year-over-year to 0.93, compared with a TTM value of 0.93 through Dec 2025, up 23.13%, and an annual FY2025 reading of 0.93, up 23.13% over the prior year.
- Equity Ratio was 0.93 for Q4 2025 at Immunome, up from 0.88 in the prior quarter.
- Across five years, Equity Ratio topped out at 0.93 in Q4 2025 and bottomed at 0.07 in Q3 2023.
- Average Equity Ratio over 3 years is 0.7, with a median of 0.85 recorded in 2024.
- Peak annual rise in Equity Ratio hit 1182.64% in 2024, while the deepest fall reached 6.56% in 2024.
- Year by year, Equity Ratio stood at 0.81 in 2023, then dropped by 6.56% to 0.75 in 2024, then increased by 23.13% to 0.93 in 2025.
- Business Quant data shows Equity Ratio for IMNM at 0.93 in Q4 2025, 0.88 in Q3 2025, and 0.91 in Q2 2025.